G7 Summit Postponed Amid Trump Birthday Conflict
Inflation Reduction Act Impacts on Prescription Drug Costs
Table of Contents
The Inflation Reduction Act (IRA), signed into law on August 16, 2022, represents a notable overhaul of prescription drug pricing in the United States, allowing Medicare to negotiate prices for certain high-expenditure drugs and capping out-of-pocket costs for beneficiaries. These changes aim to lower healthcare expenses for seniors and individuals with disabilities.
Medicare Drug Price Negotiation
The Inflation Reduction Act empowers the Centers for Medicare & Medicaid Services (CMS) to directly negotiate prices for a limited number of high-cost prescription drugs covered under Medicare Part D and Part B, starting in 2026.
Prior to the IRA, Medicare was largely prohibited from negotiating drug prices with pharmaceutical companies. This lack of negotiation power contributed to significantly higher drug costs in the U.S. compared to other developed nations. The IRA changes this by allowing CMS to select drugs for negotiation based on factors like high Medicare spending and lack of generic or biosimilar competition. Negotiations will occur over several years, with the first negotiated prices taking effect in 2027.
Example: CMS released its initial list of 10 drugs selected for price negotiation on August 29, 2023, including drugs to treat diabetes, heart failure, and blood clots. Details of the selected drugs are available on the CMS website.
Negotiation Timeline and Drug Selection
The IRA outlines a phased implementation of drug price negotiation. Initially, 10 drugs will be selected for negotiation between 2026 and 2029, increasing to 15 drugs between 2027 and 2030, and eventually to 20 drugs between 2028 and 2031. The full text of the IRA details the specific timelines and criteria for drug selection.
Drugs eligible for negotiation must have been on the market for at least nine years (11 years for biologics) and lack generic or biosimilar competition. This provision aims to protect pharmaceutical innovation while addressing the cost of established medications.
out-of-Pocket Cost Caps for Medicare Beneficiaries
The IRA introduces a $2,000 annual out-of-pocket spending cap for prescription drugs under Medicare part D, beginning in 2025. This cap applies to covered drugs and includes both brand-name and generic medications.
Currently, Medicare beneficiaries face potentially unlimited out-of-pocket costs for prescription drugs.This can create a significant financial burden, particularly for individuals with chronic conditions requiring expensive medications.The $2,000 cap provides financial relief and predictability for beneficiaries.
Evidence: According to a report by the Kaiser Family Foundation (KFF), approximately 1.4 million Medicare beneficiaries spent more than $2,000 out-of-pocket on prescription drugs in 2020.The IRA’s cap will directly benefit these individuals.
impact on Insulin Costs
The IRA also includes a provision capping the monthly cost of insulin at $35 for Medicare beneficiaries, effective January 1, 2023. This applies to insulin covered under Medicare Part D and Part B. CMS provides detailed information on the insulin cost cap.
Prior to this provision, the cost of insulin varied significantly, and many beneficiaries faced considerable out-of-pocket expenses. The $35 cap provides immediate relief for individuals with diabetes who rely on insulin to manage their condition.
Pharmaceutical Industry Response and Legal Challenges
The pharmaceutical industry has strongly opposed the IRA’s drug price negotiation provisions, arguing that they will stifle innovation and reduce investment in research and development. Several pharmaceutical companies and industry groups have filed lawsuits challenging the constitutionality of the law.
Legal Challenge: The U.S. Supreme Court rejected a challenge to the Inflation Reduction Act on january 9, 2024, allowing the drug price negotiation provisions to move forward. The court found that the pharmaceutical companies lacked standing to sue.
The industry maintains that the IRA will lead to fewer new drugs being developed and brought to market. Though, supporters of the law argue that it will make prescription drugs more affordable and accessible without significantly impacting innovation.